Clinical Edge Journal Scan

Lung cancer: Noncancerous chest CT features may boost survival prediction


 

Key clinical point : In patients with stage I lung cancer treated with stereotactic body radiation therapy (SBRT), a model incorporating noncancerous imaging features on chest computed tomography (CT) and clinical features vs clinical features alone performed better at predicting overall survival (OS).

Major finding : The model that incorporated both clinical and imaging features vs the model that incorporated only clinical features performed better at predicting 5-year OS (area under the curve 0.75 vs 0.61; P < .01). Independent risk factors for shorter OS were elevated coronary artery calcium score, increased pulmonary artery-to-aorta ratio, and decreased thoracic skeletal muscle index.

Study details : The data come from a retrospective study involving 282 patients with stage I lung cancer treated with SBRT. Several clinical markers were assessed from pretreatment chest CT images.

Disclosures: No funding information was available. The corresponding author FJ Fintelmann reported no relevant financial relationships.

Source: Tahir I et al. Utility of noncancerous chest CT features for predicting overall survival and noncancer death in patients with stage I lung cancer treated with stereotactic body radiotherapy. AJR Am J Roentgenol. 2022 (Apr 13). Doi: 10.2214/AJR.22.27484

Recommended Reading

Women with lung cancer live longer than men
MDedge Hematology and Oncology
Improved cancer survival in states with ACA Medicaid expansion
MDedge Hematology and Oncology
Some smokers don’t get lung cancer; genetics might explain it
MDedge Hematology and Oncology
Resectable NSCLC: The addition of nivolumab to neoadjuvant chemotherapy is beneficial
MDedge Hematology and Oncology
Advanced NSCLC: Noncachexic patients with adipose tissue loss may respond more favorably to immunotherapy
MDedge Hematology and Oncology
ALK- and ROS1-rearranged advanced NSCLC: Anticoagulants linked to worse outcomes
MDedge Hematology and Oncology
Advanced NSCLC: Real-world long-term survival outcomes of ICI-treated patients
MDedge Hematology and Oncology
NSCLC with brain metastasis: ICI-radiotherapy combo prolongs OS vs chemoradiotherapy
MDedge Hematology and Oncology
Small-sized peripheral NSCLC: Segmentectomy noninferior to lobectomy for OS
MDedge Hematology and Oncology
Extensive-stage SCLC: Anlotinib plus platinum-etoposide shows promise
MDedge Hematology and Oncology